Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Crohn's Disease Excellence Forum

Crohn's Disease
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Miguel Regueiro MD
Conference Coverage
Miguel Regueiro, MD, on Postoperative Crohn's Disease
05/15/2024
Dr Regueiro recaps his keynote address on the management postoperative Crohn's disease, including new surgical techniques and medications that could help prevent the occurrence of postoperative disease.
Dr Regueiro recaps his keynote address on the management postoperative Crohn's disease, including new surgical techniques and medications that could help prevent the occurrence of postoperative disease.
Dr Regueiro recaps his keynote...
05/15/2024
Advances in Inflammatory Bowel Disease Network
fecal calprotectin test
News
Fecal Calprotectin: Effective Marker In Understanding Progression of Crohn's Disease
05/09/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of...
05/09/2024
Advances in Inflammatory Bowel Disease Network
News
Biomarker Study Finds ‘Clearcut’ Case for Early Advanced Therapy for CD
04/08/2024

Jolynn Tumolo

Jolynn Tumolo
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly...
04/08/2024
Advances in Inflammatory Bowel Disease Network
News
Shared Gut Dysbiosis in Crohn’s Disease, Spondyloarthritis, & Acute Anterior Uveitis
03/06/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a...
03/06/2024
Advances in Inflammatory Bowel Disease Network
Florian Rieder
Video
Detection and Treatment of Stricturing Crohn's Disease
02/29/2024

featuring Florian Rieder, MD

featuring Florian Rieder, MD
Dr Rieder, from the Cleveland Clinic, reviews his talk on the detection and treatment of stricturing Crohn's disease, including medical therapy, endoscopy, and surgery, which he presented at the Advances in Inflammatory Bowel Diseases...
Dr Rieder, from the Cleveland Clinic, reviews his talk on the detection and treatment of stricturing Crohn's disease, including medical therapy, endoscopy, and surgery, which he presented at the Advances in Inflammatory Bowel Diseases...
Dr Rieder, from the Cleveland...
02/29/2024
Advances in Inflammatory Bowel Disease Network
Andres Yarur
Videos
Sherman Emerging Leader Prize 2023: Andres Yarur, MD
12/06/2023
Andres Yarur, MD, received this year’s Sherman Emerging Leader Prize for “Excellence in Crohn’s and Colitis.”
Andres Yarur, MD, received this year’s Sherman Emerging Leader Prize for “Excellence in Crohn’s and Colitis.”
Andres Yarur, MD, received this...
12/06/2023
Advances in Inflammatory Bowel Disease Network
Sara El Ouali
Conference Coverage
Non-Antitumor Necrosis Factor Biologics For Stricturing Crohn's Disease
11/10/2023

featuring Sara El Ouali, MD

featuring Sara El Ouali, MD
Dr El Ouali, from Cleveland Clinic Abu Dhabi, discusses research she and colleagues presented at DDW 2023 on the efficacy of non-antitumor necrosis factor biologics, including vedolizumab, in treatment of patients with stricturing Crohn's...
Dr El Ouali, from Cleveland Clinic Abu Dhabi, discusses research she and colleagues presented at DDW 2023 on the efficacy of non-antitumor necrosis factor biologics, including vedolizumab, in treatment of patients with stricturing Crohn's...
Dr El Ouali, from Cleveland...
11/10/2023
Advances in Inflammatory Bowel Disease Network
Jessica Allegretti, MD
Conference Coverage
Optimizing Existing Therapies in the Management of IBD: Dr Jessica Allegretti
07/21/2023

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Jessica Allegretti, MD, from Brigham and Women's Hospital, identified high risk factors for progressive disease, reviewed monotherapy vs combination therapy, and emphasized on the importance of treat-to-target at the AIBD meeting.
Jessica Allegretti, MD, from Brigham and Women's Hospital, identified high risk factors for progressive disease, reviewed monotherapy vs combination therapy, and emphasized on the importance of treat-to-target at the AIBD meeting.
Jessica Allegretti, MD, from...
07/21/2023
Advances in Inflammatory Bowel Disease Network
Florian Rieder, MD
Conference Coverage
Florian Rieder, MD, on Biologic Agents in IBD Management
06/16/2023

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Florian Rieder, MD, addressed the optimal positioning of antitumor necrosis factors and anti-integrins among patients with Crohn disease and ulcerative colitis.
Florian Rieder, MD, addressed the optimal positioning of antitumor necrosis factors and anti-integrins among patients with Crohn disease and ulcerative colitis.
Florian Rieder, MD, addressed...
06/16/2023
Advances in Inflammatory Bowel Disease Network
Stefan Holubar, MD
Conference Coverage
Stefan Holubar, MD, on Advances in the Management of Fistulizing CD
06/15/2023

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Stefan Holubar, MD, emphasized the need to implement coordinated, patient-centered management strategies based on the most current evidence and consensus-based guidelines in managing fistulizing Crohn disease.
Stefan Holubar, MD, emphasized the need to implement coordinated, patient-centered management strategies based on the most current evidence and consensus-based guidelines in managing fistulizing Crohn disease.
Stefan Holubar, MD, emphasized...
06/15/2023
Advances in Inflammatory Bowel Disease Network

Advertisement

Latest News

fecal calprotectin test
News
Fecal Calprotectin: Effective Marker In Understanding Progression of Crohn's Disease
05/09/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of...
05/09/2024
Advances in Inflammatory Bowel Disease Network
News
Biomarker Study Finds ‘Clearcut’ Case for Early Advanced Therapy for CD
04/08/2024

Jolynn Tumolo

Jolynn Tumolo
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly...
04/08/2024
Advances in Inflammatory Bowel Disease Network
News
Shared Gut Dysbiosis in Crohn’s Disease, Spondyloarthritis, & Acute Anterior Uveitis
03/06/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a...
03/06/2024
Advances in Inflammatory Bowel Disease Network
News
Vedolizumab Success Rate Appears Low in Active Perianal Crohn Disease
02/21/2020
Perianal Crohn disease (CD) is persistent, and treating patients is challenging. Authors of a new study sought to assess the effectiveness of vedolizumab in perianal CD and the predictors of success in a real‐life cohort.
Perianal Crohn disease (CD) is persistent, and treating patients is challenging. Authors of a new study sought to assess the effectiveness of vedolizumab in perianal CD and the predictors of success in a real‐life cohort.
Perianal Crohn disease (CD) is...
02/21/2020
Advances in Inflammatory Bowel Disease Network
fecal calprotectin test
News
Fecal Calprotectin: Effective Marker In Understanding Progression of Crohn's Disease
05/09/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of...
05/09/2024
Advances in Inflammatory Bowel Disease Network
News
Study Finds Higher-Than-Expected IBD Rates in US Black Women
05/02/2024

Jolynn Tumolo

Jolynn Tumolo
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory...
05/02/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Subcutaneous Vedolizumab for Maintenance Therapy in Crohn’s Disease
04/22/2024
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug...
04/22/2024
Advances in Inflammatory Bowel Disease Network
Bharati Kochar
Conference Coverage
Bharati Kochar, MD, on Comparative Effectiveness in Positioning Therapies in Ulcerative Colitis
04/10/2024
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about considering the efficacy-safety relationship to avoid longstanding corticosteroid use or the use of less effective agents in biologic-exposed populations at the AIBD regional meeting in Boston.
Dr Bharati Kochar talks about...
04/10/2024
Advances in Inflammatory Bowel Disease Network
News
Biomarker Study Finds ‘Clearcut’ Case for Early Advanced Therapy for CD
04/08/2024

Jolynn Tumolo

Jolynn Tumolo
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly...
04/08/2024
Advances in Inflammatory Bowel Disease Network
News
Extended Mirikizumab Induction Benefits Slower Responders in UC Trials
03/20/2024

Jolynn Tumolo

Jolynn Tumolo
LUCENT trials found that 24-week induction period generated response in half of patients.
LUCENT trials found that 24-week induction period generated response in half of patients.
LUCENT trials found that 24-week...
03/20/2024
Advances in Inflammatory Bowel Disease Network
News
Shared Gut Dysbiosis in Crohn’s Disease, Spondyloarthritis, & Acute Anterior Uveitis
03/06/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a...
03/06/2024
Advances in Inflammatory Bowel Disease Network
News
Study Finds Higher-Than-Expected IBD Rates in US Black Women
02/23/2024

Jolynn Tumolo

Jolynn Tumolo
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory bowel disease was highest among Black women younger than 30 years of age.
The incidence of inflammatory...
02/23/2024
Advances in Inflammatory Bowel Disease Network
Conference Coverage
Bowel Urgency Reflected in Patient Perceptions of UC Severity
02/20/2024
How patients perceive the severity of their ulcerative colitis is affected by the frequency of bowel urgency episodes and accidents, researchers reported at the American College of Gastroenterology Postgraduate Course.
How patients perceive the severity of their ulcerative colitis is affected by the frequency of bowel urgency episodes and accidents, researchers reported at the American College of Gastroenterology Postgraduate Course.
How patients perceive the...
02/20/2024
Advances in Inflammatory Bowel Disease Network
News
Could Polygenic Risk Score Indicate Risk of Primary Sclerosing Cholangitis in IBD?
02/15/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Researchers investigated a new tool that could help predict primary sclerosing cholangitis, a chronic liver disease that is strongly associated with IBD.
Researchers investigated a new tool that could help predict primary sclerosing cholangitis, a chronic liver disease that is strongly associated with IBD.
Researchers investigated a new...
02/15/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Latest Podcasts

IBD logo
Podcast
IBD Drive Time: Importance of Diet in the Management of Crohn's Disease
05/25/2023

featuring James Lewis, MD, and Raymond Cross, MD

featuring James Lewis, MD, and Raymon...
In the third episode of IBD Drive Time, host Raymond Cross, MD, discusses research into how diet can alleviate symptoms—or worsen disease—among patients with Crohn's disease with Dr James Lewis, who conducted the DINE-CD study.
In the third episode of IBD Drive Time, host Raymond Cross, MD, discusses research into how diet can alleviate symptoms—or worsen disease—among patients with Crohn's disease with Dr James Lewis, who conducted the DINE-CD study.
In the third episode of IBD...
05/25/2023
Advances in Inflammatory Bowel Disease Network
Saurabh Mehandru
Podcast
Saurabh Mehandru, MD, on Durability of Response to p19 Inhibitors in IBD
03/24/2023
Dr. Mehandru reviews the results of 3 pivotal clinical trials on p19 inhibitors where the drug effect was found to be sustained for an extended period following drug withdrawal.
Dr. Mehandru reviews the results of 3 pivotal clinical trials on p19 inhibitors where the drug effect was found to be sustained for an extended period following drug withdrawal.
Dr. Mehandru reviews the results...
03/24/2023
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Sara Horst, MD, on Risankizumab for Crohn Disease
07/12/2022
In this episode of IBD Drive Time, hosts Raymond Cross, MD, and Millie Long, MD, talk to Dr Sara Horst of Vanderbilt University about the newly approved IL-23 inhibitor, risankizumab, and its benefit in treating inflammatory bowel disease.
In this episode of IBD Drive Time, hosts Raymond Cross, MD, and Millie Long, MD, talk to Dr Sara Horst of Vanderbilt University about the newly approved IL-23 inhibitor, risankizumab, and its benefit in treating inflammatory bowel disease.
In this episode of IBD Drive...
07/12/2022
Advances in Inflammatory Bowel Disease Network
Phillip Fleshner
Podcast
Phillip Fleshner, MD, on Perianal/Fistulizing Crohn Disease
04/30/2022
In this podcast, Dr Phillip Fleshner, director of colorectal surgery at Cedars-Sinai Medical Center in Los Angeles, discusses the complexities of medical and surgical treatment of perianal and fistulizing Crohn disease, which he spoke about...
In this podcast, Dr Phillip Fleshner, director of colorectal surgery at Cedars-Sinai Medical Center in Los Angeles, discusses the complexities of medical and surgical treatment of perianal and fistulizing Crohn disease, which he spoke about...
In this podcast, Dr Phillip...
04/30/2022
Advances in Inflammatory Bowel Disease Network
David Schwartz, MD
Podcasts
David Schwartz, MD, on the ENTERPRISE Study of Vedolizumab for Perianal Crohn Disease
12/30/2021
In this podcast, Dr Schwartz, from Vanderbilt University, discusses the ENTERPRISE multinational program that examined the efficacy and safety of vedolizumab for perianal Crohn’s disease.
In this podcast, Dr Schwartz, from Vanderbilt University, discusses the ENTERPRISE multinational program that examined the efficacy and safety of vedolizumab for perianal Crohn’s disease.
In this podcast, Dr Schwartz,...
12/30/2021
Advances in Inflammatory Bowel Disease Network
Adam Cheifetz
Podcast
Adam Cheifetz, MD, and Konstantinos Papamichail, MD, on Therapeutic Drug Monitoring in Fistulizing Crohn Disease
09/03/2021
In this podcast, Adam Cheifetz, MD, director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and associate professor at Harvard Medical School, and Konstantinos Papamichail, M.D., Ph.D., instructor in...
In this podcast, Adam Cheifetz, MD, director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and associate professor at Harvard Medical School, and Konstantinos Papamichail, M.D., Ph.D., instructor in...
In this podcast, Adam Cheifetz,...
09/03/2021
Advances in Inflammatory Bowel Disease Network
Sara Horst, MD, and David Schwartz, MD, on Current and Upcoming Treatments for Perianal Crohn Disease
Podcasts
Sara Horst, MD, and David Schwartz, MD, on Current and Upcoming Treatments for Perianal Crohn Disease
05/07/2021
In this podcast, Drs Sara Horst and David Schwartz of Vanderbilt University wrap up their podcast series on perinanal Crohn disease with a discussion of existing and upcoming therapies and procedures.
In this podcast, Drs Sara Horst and David Schwartz of Vanderbilt University wrap up their podcast series on perinanal Crohn disease with a discussion of existing and upcoming therapies and procedures.
In this podcast, Drs Sara Horst...
05/07/2021
Advances in Inflammatory Bowel Disease Network
Sara Horst, MD, and David Schwartz, MD, on Refractory Perianal Crohn's Disease
Podcasts
Sara Horst, MD, and David Schwartz, MD, on Refractory Perianal Crohn's Disease
04/26/2021
Drs Sara Horst and David Schwartz from Vanderbilt University continue their podcast series on Crohn disease in this discussion about the challenges of treating the patient with refractory Crohn disease and their approach to controlling the...
Drs Sara Horst and David Schwartz from Vanderbilt University continue their podcast series on Crohn disease in this discussion about the challenges of treating the patient with refractory Crohn disease and their approach to controlling the...
Drs Sara Horst and David...
04/26/2021
Advances in Inflammatory Bowel Disease Network
Sara Horst, MD and David Schwartz, MD, on Surgery and Therapies for Perianal Crohn Disease
Podcasts
Sara Horst, MD and David Schwartz, MD, on Surgery and Therapies for Perianal Crohn Disease
04/08/2021
In this second podcast of a series on the care of patients with perianal Crohn disease, Dr Horst and Dr Schwartz, both from Vanderbilt University, discuss when to involve a surgeon and the preferred medical therapies used to treat this...
In this second podcast of a series on the care of patients with perianal Crohn disease, Dr Horst and Dr Schwartz, both from Vanderbilt University, discuss when to involve a surgeon and the preferred medical therapies used to treat this...
In this second podcast of a...
04/08/2021
Advances in Inflammatory Bowel Disease Network
Sara Horst, MD, and David Schwartz, MD, on Managing Patient Expectations in Treating Crohn Disease
Podcasts
Sara Horst, MD, and David Schwartz, MD, on Managing Patient Expectations in Treating Crohn Disease
03/26/2021
In part 1 of a 5-part series on the challenges of treating perianal Crohn disease, Sara Horst, MD, and David Schwartz, MD, from Vanderbilt University Medical Center, discuss how to manage patient expectations concerning treatment and outcomes.
In part 1 of a 5-part series on the challenges of treating perianal Crohn disease, Sara Horst, MD, and David Schwartz, MD, from Vanderbilt University Medical Center, discuss how to manage patient expectations concerning treatment and outcomes.
In part 1 of a 5-part series on...
03/26/2021
Advances in Inflammatory Bowel Disease Network
Millie Long
Podcast
Millie Long, MD, on Comparative Effectiveness in Ulcerative Colitis
05/10/2024
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Long reviews her presentation...
05/10/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Gary Lichtenstein, MD, on the Best of ECCO
05/06/2024
IBD Drive Time continues its coverage of the European Crohn's & Colitis Organization meeting as Dr Gary Lichtenstein shares his choices on the best abstracts with host Dr Raymond Cross.
IBD Drive Time continues its coverage of the European Crohn's & Colitis Organization meeting as Dr Gary Lichtenstein shares his choices on the best abstracts with host Dr Raymond Cross.
IBD Drive Time continues its...
05/06/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Siddharth Singh: AGA Guidelines on Using Biomarkers in Ulcerative Colitis
04/25/2024
In this episode of IBD Drive Time, cohost Raymond Cross, MD, talks with Siddharth Singh, MD, about the latest guidelines from the American Gastroenterological Association on caring for patients with ulcerative colitis.
In this episode of IBD Drive Time, cohost Raymond Cross, MD, talks with Siddharth Singh, MD, about the latest guidelines from the American Gastroenterological Association on caring for patients with ulcerative colitis.
In this episode of IBD Drive...
04/25/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Jimmy Limdi, MD, on the Best of ECCO
04/22/2024
In this episode of IBD Drive Time, Dr Raymond Cross hosts Dr Jimmy Limdi from the University of Manchester to discuss his choices for the best presentations and abstracts presented at the European Crohn's and Colitis Organization meeting held...
In this episode of IBD Drive Time, Dr Raymond Cross hosts Dr Jimmy Limdi from the University of Manchester to discuss his choices for the best presentations and abstracts presented at the European Crohn's and Colitis Organization meeting held...
In this episode of IBD Drive...
04/22/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Patrick Young, MD, on Ergonomics and Endoscopy
03/29/2024
Dr Patrick Young, from the Uniformed Services University and Walter Reed National Military Medical Center in Washington, DC, provides guidance in how to prevent injury and discomfort when performing endoscopy in this episode of IBD Drive Time...
Dr Patrick Young, from the Uniformed Services University and Walter Reed National Military Medical Center in Washington, DC, provides guidance in how to prevent injury and discomfort when performing endoscopy in this episode of IBD Drive Time...
Dr Patrick Young, from the...
03/29/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcasts
IBD Drive Time: Corey Siegel, MD, on Caring for the Patient with Acute Severe UC
03/20/2024
In this episode of IBD Drive Time, Dr Raymond Cross and guest Dr Corey Siegel review the key issues surrounding the care of patients hospitalized due to acute severe ulcerative colitis.
In this episode of IBD Drive Time, Dr Raymond Cross and guest Dr Corey Siegel review the key issues surrounding the care of patients hospitalized due to acute severe ulcerative colitis.
In this episode of IBD Drive...
03/20/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Millie Long, MD, on Insurance Barriers to IBD Care
03/14/2024
Dr Millie Long and her IBD Drive Time cohost, Dr Raymond Cross, talk about ways health insurers create barriers to timely treatment for inflammatory bowel disease, particularly through requirements for prior authorization.
Dr Millie Long and her IBD Drive Time cohost, Dr Raymond Cross, talk about ways health insurers create barriers to timely treatment for inflammatory bowel disease, particularly through requirements for prior authorization.
Dr Millie Long and her IBD Drive...
03/14/2024
Advances in Inflammatory Bowel Disease Network
Podcast
Ryan Ungaro, MD, and Priscila Santiago, MD, on Risk Factors Predictive of Complicated IBD
03/11/2024
In this podcast, Drs Ryan Ungaro and Priscila Santiago discuss their study of risk factors that may be predicators of complications among patients with IBD.
In this podcast, Drs Ryan Ungaro and Priscila Santiago discuss their study of risk factors that may be predicators of complications among patients with IBD.
In this podcast, Drs Ryan Ungaro...
03/11/2024
Advances in Inflammatory Bowel Disease Network
Raymond Cross, MD
Video
Raymond Cross, MD: Define UC Disease Severity in Regard to Symptoms
02/26/2024
Dr Cross reviews the highlights of his presentation on recommendations for initial diagnostics and treatment in the care of the hospitalized patient with ulcerative colitis.
Dr Cross reviews the highlights of his presentation on recommendations for initial diagnostics and treatment in the care of the hospitalized patient with ulcerative colitis.
Dr Cross reviews the highlights...
02/26/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Ed Barnes, MD, on AGA Guidelines on Pouchitis
02/21/2024
Dr Ed Barnes from University of North Carolina at Chapel Hill discusses the new guidelines from AGA on the treatment of pouchiitis among patients who have undergone ileal pouch-anal anastamosis surgery.
Dr Ed Barnes from University of North Carolina at Chapel Hill discusses the new guidelines from AGA on the treatment of pouchiitis among patients who have undergone ileal pouch-anal anastamosis surgery.
Dr Ed Barnes from University of...
02/21/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement